Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for locally advanced head and neck squamous cell carcinoma.

Autor:	Han, Ping, Liang, Faya, Song, Pan, Wu, Taowei, Li, Yangyang, Gao, Ming, Lin, Peiliang, Fan, Jianming, Huang, Xiaoming
Předmět:	THERAPEUTIC use of antineoplastic agents THERAPEUTIC use of monoclonal antibodies SQUAMOUS cell carcinoma DRUG toxicity BIOPSY CISPLATIN SURVIVAL rate DRUG side effects LYMPHADENECTOMY ACADEMIC medical centers CANCER relapse HEAD & neck cancer PROGRAMMED death-ligand 1 IMMUNOTHERAPY ANTINEOPLASTIC agents PATHOLOGIC complete response CANCER patients RETROSPECTIVE studies DESCRIPTIVE statistics MANN Whitney U Test IMMUNE checkpoint inhibitors CANCER chemotherapy KAPLAN-Meier estimator THROMBOCYTOPENIA LONGITUDINAL method METASTASIS COMBINED modality therapy DRUG efficacy FLUOROURACIL PACLITAXEL COMPARATIVE studies PROGRESSION-free survival DATA analysis software TREATMENT delay (Medicine) OVERALL survival NEUTROPENIA CHEMICAL inhibitors
Zdroj:	Holistic Integrative Oncology; 6/27/2024, Vol. 3 Issue 1, p1-11, 11p
Abstrakt:	Purpose: Anatomical structures and organ preservation concepts of the head and neck are important for patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC). Neoadjuvant chemotherapy has been applied to improve organ preservation; however, pathological complete remission is still unsatisfactory. The purpose of this study was to explore the pathological complete response (pCR) rate and safety of immune checkpoint blockade combined with neoadjuvant chemotherapy (NAC) in patients with LA HNSCC. Methods: Fifty-one patients participated in this retrospective study, and of these, 25 received NAC only (cisplatin+5-fluorouracil+nab-paclitaxel), and 26 received NAC (cisplatin+5-fluorouracil) plus pembrolizumab. Pathological complete remission, the objective response rate (ORR), delayed surgery and toxicity were compared between the two groups. Results: A significant difference was observed in the pCR rate and ORR between the NAC+ICB group and the NAC group. Delaying surgery and Grade 3 or 4 AEs occurred more frequently in the NAC group. In the NAC-only group, during a median follow-up period of 31.80 months, the recurrence-free survival (RFS) rate was 80.0%, the disease-free survival (DFS) rate was 80.0% and the overall survival (OS) rate was 88.0%. In the NAC+ICB group, during the median follow-up period of 22.99 months, the RFS rate was 96.2%, the DFS rate was 96.2% and the OS rate was 100%. Conclusion: The combination of pembrolizumab with NAC could improve the pathological response without increasing the risk of toxicity, which provides pathological evidence for the treatment of LA HNSCC patients with NAC+ICB. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink